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Several low molecular weight compounds are capable of activating soluble guanylyl cyclase. Recent evidence suggests hat some of these are formed 
under physiological conditions: the nitric oxide radical, carbon monoxide and the hydroxyl radical. Thus, multiple signal transduction pathways 
appear to exist that form a family of guanylyl cyclase activating faclors and thereby regulate the intracellular cyclic guanosine 3’,5’-monophosphatc 
Ievcl. 
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1. INTRODUCTION 
The second messenger molecule guanosine cyclic 
3’,5’-monophosphate (cGMP) regulates various protein 
kinascs, nucleosid 3’,5’-monophosphate phosphodies- 
terases and ion channels [I], Its intracellular concen- 
tration is regulated by cGMP-forming enzymes, i.e. 
guanylyl cyclases (GTP pyrophosphate-lyase (cy- 
clizing), EC 4.6. I A?), and cGMP-degrading enzymes, i.e. 
cGMP phosphodiesterases [2]. 
2. SOLUBLE GUANYLYL CYCLASES 
Guanylyl cyclases can be classified into soluble (GC- 
S) and particulate isoforms. In all particulate guanylyl 
cyclases (detergent-extractable or cytoskeletal) a single 
transmembrane domain separates the intracellular cata- 
lytic portion from an extracellular receptor portion for 
different peptides, e.g. natriuretic peptides [3] or gua- 
nylin [4], which stimulate nzyme activity. 
GC-S are not activated by these peptides and have a 
different structure. They are heterodimeric proteins 
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which exhibit the typical visual absorption spectrum of 
hemoproteins, a pyridine hemochrome spectrum corre- 
sponding to that of ferroprotoporphyrine IX [S] and, in 
addition to iron, contain copper as another transition 
metal [S]. Unlike the particulate isozymes, the regula- 
tion of GC-S activity is much less understood. It has 
been suggested that GC-S activity is regulated by Ca’+- 
dependent [6] and redox [3,7] mechanisms. Recent data 
suggest hat this regulation is mediated by a family of 
endogenously formed guanylyl cyclase-activating-fac- 
tors (GAFs) [S], i.e. low molecular weight monoxides of 
nitrogen (NO), carbon (CO) or hydrogen (01-I). Their 
formation [9,10] is catalyzed by different GAF syn- 
tbases (Fig, I), some of which can be transcriptionally 
induced. 
3. NITRIC OXIDE 
Nitric oxide (NO) is formed enzymatically from a 
terminal guanidino-nitrogen of L-arginine 11 l-l 31 by 
so-called NO synthases (NOSs) that yield L-citrulline as 
a co-product. The mechanism, an unusual five-electron 
oxidation, has not been elucidated but two intermedi- 
ates NG-hydroxy-L-arginine [ 141 and a jV”-hydroxy-cat- 
ion radical [ 151 have been postulated. Alternatively, the 
latter compound may represent the endproduct of enzy- 
matic conversion of L-arginine and may spontaneously, 
i.e. non-enzymatically, decompose to release NO. After 
its formation, NO may also be stabilized by thiols 
[ 16,171 procluding its detection as a free radical [18,191. 
So far, three families of NOS exist [S] (Table I). The 
basis for their classification is subcellular location and 
regulation by the free Ca” (usually mediated by cal- 
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Fig. I. Regulation of soluble guanylyl cyclase (CC-S) by different 
guanylyl cyclase-activating factors (CiAFs). The 1st messcngcr path- 
ways summarize (from left to right) the following GAF synthesizing 
enzyme systems: nitric oxide synthase (NOS), lipid pcroxidation 
(LPO). heme oxygcnase (HO), xamhine oxidasc (XOD) and the non- 
enzymatic iron.catnlyzed Habcr-W&s reaction. 
modulin). Types I and 111 are constitutively expressed 
whereas type II is expressed only after immunological 
activation of cells with different cytokines or endotoxin. 
NOSs require t,-arginine, molecular oxygen, 
NADPH, and/or contain tetrahydrobiopterin (H4biop- 
terin) [20,21], FAD [22], FMN [23-251, and iron [24], 
respectively, classifying NOSs as biopteroflavo proteins 
[25]. The homodimer epresents he native form of NOS 
[S]; the monomeric protein is inactive, and dimerization 
requires H4biopterin 1263. From the primary structure 
of NOS, one mole of each flavin and NADPH would 
be predicted per monomer [23]. Upon dimerization, 
binding sites for some cofactors appear to dissociate 
into high and low affinity sites resulting in a recovery 
or incorporation of less than one mol cofactor per mon- 
omer [X]. Non-stoichometric amounts of exogenous 
FAD [22] and H,biopterin [8,27] stimulate the activity 
of purified NOS, possibly by occupying the respective 
low-affinity binding site in the dimeric complex. The 
degree of activation of NOS that can be achieved by 
exogenous H,biopterin inversely correlates to the 
amount of enzyme-bound cofactor, which explains ap- 
parently contradictory initial reports on the role of 
H,biopterin in NOS catalysis [8,27-301. In al! !inown 
H,biopterin-utilizin g enzymes, the quinoid form of 
H,biopterin (q-H?biopterin) is the product of normal 
catalysis and is regenerated to H,biopterin by a q-H2bi- 
opterin reductase (dihydropteridine r ductase). Purified 
NOS contains biopterin only in its fully reduced form 
(H,biopterin) which may indicate a q-H,biopterin re- 
ductase activity [25] by which NOS NADPH-depen- 
dently recycles H,biopterin. Alternatively, it was sug- 
gested that H,biopterin acts as an allosteric activator of 
NOS and is not oxidized during normal catalysis [30]. 
The biopterin binding site of NOS may, however, be 
different from the one in any known H,biopterin-me- 
tabolizing enzyme as indicated by unique K,, values 
[3 1.321, substrate specificity [20,21,30] and resistance to 
inhibition by mcthotrexate [30]. 
The putative q-H?biopterin reductase activity of NOS 
may in part or completely be related to its NADPH- 
diaphorase activity [33], i.e. the ability of NOS to reduce 
nitroblue tetrazolium to a blue diformazan. This activ- 
ity is remarkably stable enabling the convenient locali- 
zation of NOS in fixed tissue sections [33,34]. NOS also 
reduces the cytochromcs c [I l] and PdsO [35]. Notably, 
the turnover number for cytochrome c is almost two 
orders of magnitude higher than that for L-arginine [35]; 
in conjunction with the reported sequence homologies 
1231, the latter activity would qualify NOS also as an 
isoform of microsomal NADPH-cytochrome P450 re- 
ductase (CPR). In the case of NOS type I, O2 uptake 
displays the same Ca”-dependency, as does L-argininc 
turnover [24]. Non-heme iron is possibly involved in the 
electron transfer from NADPH to oxygen [24,2a (Fig. 
2) and, in the absence of L-arginine, NOS becomes an 
NADPH oxidase, i.e. generates HZOZ 1241. 
The Ca!+-independent NOS type 11 is not constitu- 
tively expressed. Its induction by cytokines is transcrip- 
tionally based and can be suppressed by glucocorticoids 
[36]. A similar effect on cytokine-mediated induction 
was recently described for certain serine protease inhib- 
itors [37-391; however, their mechanisms i unrelated to 
proLease inhibition but involves interference with pro- 
tein synthesis [40] and intracellular thiol pools [41]. Fur- 
thermore, cytokincs can also down-regulate the expres- 
sion of constitutive NOS (Ca’+dependent type I) by 
mechanisms which are yet unclear [39]. Once expressed, 
phosphorylation may be a common regulatory mecha- 
nism for all known isoforms of NOS. The predicted 
amino acid sequence of the NOS type 1 cDNA contains 
consensus ites for phosphorylation by CAMP-depend- 
ent protein kinases [23]. Although forskolin-induced in- 
creases in intracellular CAMP levels [39] and CAMP- 
dependent protein kinases [42] do not regulate NOS 
activity, protein kinase C and Ca’+/calmodulindepend- 
ent kinase [433 and the phosphatase inhibitor okadaic 
acid [39] clearly modulate NOS activity. 
The subcellular localization of the various NOS is 
different, and also the same isoform may be distributed 
between the soluble and particulate subcellular fraction 
[39]. Since none of the described NOS appear to have 
a transmembrane domain ([23,44] and T. Michel. per- 
sonal communication), co- or posttranslational modifi- 
cations, e.g. myristilation, palmitation, isoprenylation 
and/or glycosylation, may regul&e the subcellular IOcdl- 
ization of the enzyme and represent an additional mech- 
anism of regulation of its activity. 
Long before its endogenous biosynthesis was discov- 
ered, NO [45] and NO-containing compounds such as 
sodium nitroprusside [46,47] were known to potently 
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activate GC-S. These early studies partially elucidated 
the mechanism of action of NO, which binds to the 
heme moiety of GC-S, dislocates the heme-iron and 
thereby induces a confor;national change of the protein 
which in turfi activates the catalytic site [48]. Heme-free 
GC-S no longer responds to NO [5,48]. Some aspects of 
this proposed mechanism, however, still need experi- 
mental support. 
4. CARBON MONOXIDE 
Carbon monoxide (CO) is detected in the exhaled air 
of mammals [49] (recently also shown for NO [SO]). It 
can be generated endogenously from at least two bio- 
logical sources, fatty acids and heme, and both proc- 
esses appear to be enzymatic. 
NADPH-dependent enzymatic peroxidation of mi- 
crosomal membrane lipids, e.g. methyl linolenute [49] 
and other polyunsaturated fatty acids, can produce a 
carbon chain cleavage [51] and eventually CO [52,53]. 
In microsomal preparations, the formation oi’ CO is 
quantitatively sufficient o cause the characterislic P.,sO- 
CO absorbance spectrum iS3,54]. Lipid peroxidation 
and CO formation can be further enhanced by iron and 
chelators such as adenosine diphosphate (ADPFe3+) 
and parallels that of malondialdehyde formation [54]. 
Table 1 
Classification and properties of NO and CO synthesizing enzyme5 
NO synthase NADPH 
cytochrome P450 
reductase 
Heme oxygenase 
EC. 1.14.23 1.6.2.4 1 J4.99.3 
Reaction L-arginine -+ NO + 
L-citrulline 
heme 3 CO + 
propentdyopent 
heme + CO + biliverdin IXa 
+ iron 
Isoforms 
Subcellular 
Location 
Mass, 
Denatured 
Native 
State 
Induction 
Type 1 
soluble 
16OkD 
11 III 
particulate> 
solubie 
kD 
dimer 
E 
endotoxin 
Regulation 
NADPH 
FAD, FAD, FAD, 
Hqbiopterin Hdbiopterin 
free fl Cal* 
phosphor. 
homologous Cytochrome 
microsomal 
kD 
phenobarbital 
FAD, 
homologous NO 
b 
?Lpe 
microsomal 
Type 
microsomal 
kD 
monomer 
heat 
hematin 
ion5 
NADPH 
heme substrate) 
Cytochrome 
reductase reductase 
in cases by I’ on homology the characteristic cytochromc reduction NO 
may considered isororm NADPH-cytochromc rcductasc. down by cndotoxin 
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Moreover, cytochrome 6s or another microsomal com- 
ponent closely related to cytochrome PJsO can function 
as a peroxidasc [SS] (see below) rind may, therefore, also 
play a role in microsomal enzymatic CO formation. 
At least three enzymatic’ systems for oxidative heme 
destruction have been identified and all have destinct 
mechanisms. However, all have in common to generate 
CO, utilize NADPH and O?, and to depend on CPR. 
First, the bulk of in vivo heme metabolism is believed 
to be provided by a mixed function oxidase which con- 
sists of CPR and the heme-binding and heat-shock [58] 
protein heme, hydrogen donor:oxygen oxidoreductase 
(a-methene-oxidizing, hydroxylating) termed heme oxy- 
genase. This two-enzyme system converts iron proto- 
porphyrine IX (FePPIX) and several other hemopro- 
teins yielding biliverdin IXa and CO. Second, P,,, is 
destroyed uring microsomal lipid peroxidation?, which 
process will yield CO [53]. Third, P,,, and FePPIX are 
destroyed in the presence of CPR [59, 631 by a mecha- 
nism that appears to be distinct from that in which heme 
oxygenase converts heme Lo biliverdin [63]. Because of 
the numerous imilarities between NOS and CPR, some 
isoforms of NOS may also share this heme degrading 
activity of CPR. Moreover, under certain conditions the 
heme moiety of GC-S may represent an alternate sub- 
strate for heme oxygenase and the other described heme 
degrading mechanisms. It is intriguing that intracellular 
GC-S activity might be downregulated by such mecha- 
nisms. 
The activation of GC-S by CO in vitro [64] and in 
isolated cells [65,66] has effects imilar to NO, i.e. inhi- 
bition of platelet aggregation [65] and vascular smooth 
muscle relaxation [67], and is accompanied by increases 
in intraceliular CAMP. The characteristics and mecha- 
nism of GC-S activation by CO also seem to be identical 
with NO [65]. The fact that hemin [68], heme [69] and 
tin [70], all potent metabolic inducers of heme oxyge- 
nase, all lower blood pressure in spontaneously hy- 
pertensive rats suggests that endogenous CO formation; 
can be suficient in vivo to stimulate vascular smooth 
muscle GC-S and induce vasodilatation. 
5. HYDROXYL RADICAL 
The hydroxyl radical (OH) has been shown to activate 
GC-S, whereas other oxygen radicals are either inhib- 
itory (superoxide anion) or have no effect (peroxide). 
OH was, therefore, suggested to function as a physio- 
‘Degradation of heme and hcmoprotcins lo bile pigments has also 
been described in coupled systems using ascorbate or mild reducing 
agents [S6]. This mechanism is thought to account for the artiftiactual 
‘heme a-methcnyl oxygenasc’ activity reported by Nakajima [57]. 
‘P.,,, is also destroyed by products of its mixed function oxidative 
metabolism of certain olefins, such as vinyl chloride [S9], secoburbital 
[60], and allylisopropylacctamidc [Gl]. 
L-arglnlne 
NADPtl+H+ -
.*DpXI+*JC Ii r 
NG=Ot\+arglnine 
Fig. 2. Three activities of NOS: L-argininc dioxygcnasc. NADPH- 
diaphorasc and q-H2biopicrin reductasc (modified from ref. [25]). 
Molecular oxypcn (dioxygenase) is incorporated into both NO and 
L-citrullinc [S?]. in the case of NOS type 1, oxygen consumption is 
Ca’+/CnM-depcndenl [24], Non-hcme iron may be involved in the 
electron transfer to oxygen [34]. The primary rcacdon is the hydroxyl.. 
alion oT L-argininc which requires I mol of the electron donor 
NADPH. The oxidation ofthe intermediate p-hydroxy+argininc to 
L-citrullinc requires an additional 0.5 mol NADPH [14] and is dcpcnd- 
cnl on I-l,bioptcrin. NOS has bound stoichomctric amounts of its 
cofactors H,biop\erin. FAD and FMN. It was suggested [?5] that iron 
and flavins are part of different domains and that M,bioptcrin is 
recycled in a Ca’+/CaM-independent fihion. This yet putative q- 
H,biopterin reductasc activity may bc closely related to the NADPH- 
diaphorase activity of NOS (reduction of Nivoblue tetrazolium, 
NBT). NBT also non-competitively inhibits theconvcnion ofL-argin- 
ine [25]. 
logical GAF [71] and, in mouse cerebral arterioles [72], 
as the mediator of endothelium-dependent 
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but not superoxide, is an intermediate in this reaction. 
Which of the mentioned sources for OH, enzy;uzic or 
non-enzymatic, is quantitatively more relevant for GC- 
S activation remains to be determined. The relative im- 
portance of each of these pathways may also vary be- 
tween different tissues and oxygen tensions. The per- 
oxynitrite pathway, for example, is likely to operate 
when in a given biological system sufficient concomitant 
NO and superoxide formation take place [?G] as is the 
case in reperfused tissue [81]. However, OH (and NO) 
is also highly cytotoxic. Depending on its concentration, 
activation of 02-S or tissue damage can, therefore, be 
expected. 
6. CONCLUSION 
Several potent and physiological GAFs have been 
identified, most of which are synthesized enzymatically. 
The role of endogenous NO as a signal transduction 
molecule regulating soluble guanylyl cyclase activity is 
clearly established. Evidence for a similar role for en- 
dogenous CO and OH is strong but yet mostly indirect. 
The mechanisms of GAF formation imply that cGMP 
levels function as a sensor for intracellular events uch 
as Ca”’ movements, heat shock, and redox status. 
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